The Anti-Aging Pill for Dogs Is Almost Here — and the FDA Is Backing It
A San Francisco biotech has cleared two of three FDA requirements for a daily longevity pill for senior dogs — a drug that could add meaningful healthy years to your dog's life. The largest clinical trial in veterinary history is already underway. Here's where it stands.
The hardest part of loving a dog
Every dog owner knows how the story ends. You know it from the beginning — from the moment that puppy looks up at you. What you can't know is how much time you have, or whether the last years will be good ones. A San Francisco biotech called Loyal has spent the last six years trying to change that math, and they're now closer than anyone has ever been.
What LOY-002 actually is
LOY-002 is a daily prescription pill designed for senior dogs — currently targeting dogs 10 years and older, weighing at least 14 lbs. It works as a caloric restriction mimetic: it delivers some of the biological benefits of a severely reduced-calorie diet — improved metabolic function, reduced age-related disease burden — without actually cutting food intake or causing weight loss.
That last part matters enormously for anyone who has tried to put a food-motivated dog on a diet.
The science behind the concept is grounded in a landmark Purina study that found calorie-restricted dogs lived roughly two years longer on average than their littermates, with delayed onset of cancer and osteoarthritis. LOY-002 aims to capture those gains without the suffering (or the refusal to comply) that real caloric restriction requires.
"Part of the genius of the idea of LOY-002 is that it achieves some of the same goals biologically as caloric restriction without the hardship and the risks," said Dr. Brennen McKenzie, Loyal's Director of Veterinary Medicine, speaking to Fortune. "It doesn't require restricting calories, and it doesn't cause them to lose weight."
The FDA pathway — and where it stands right now
Loyal is pursuing conditional FDA approval — a pathway designed for exactly this situation: a drug that has demonstrated safety and a reasonable expectation of efficacy, but whose full long-term study isn't yet complete. Three major technical acceptances are required.
As of now, LOY-002 has cleared two of the three:
- ✅ Reasonable Expectation of Efficacy (RXE) — FDA's formal acceptance that the drug can plausibly extend canine lifespan. Loyal has earned this twice over: LOY-001 (for large dogs) was the first-ever RXE for a longevity drug for any species; LOY-002 is the second.
- ✅ Target Animal Safety (TAS) — FDA acceptance of the safety data package, cleared in January 2026.
- 🔄 Manufacturing — the final formal requirement before conditional approval, in progress.
If manufacturing acceptance comes through, Loyal could reach the market with the first FDA-approved longevity drug for any species in history — including humans.
"If we get approval for this drug, it'll be the first time any aging drug, any lifespan drug, has been approved for any species," McKenzie told Fortune. "I hope it'll open some doors scientifically."
The largest clinical trial in veterinary history
Alongside the regulatory process, Loyal is running the STAY study — 1,300 dogs across 72 veterinary clinics nationwide, in a randomized, double-blinded, placebo-controlled design. When they announced they'd try to enroll 1,000 dogs, the scientific community told them it was impossible. Over 12,000 people emailed in wanting to participate.
That number tells you everything about where dog owners are emotionally on this.
"A lot of them say, 'I know this may not be helpful for my dog, but the idea that I can contribute to having something that will give my future dogs and other people's dogs more time is really motivating,'" McKenzie said.
The study, now about two and a half years in, will run a minimum of four years — but crucially, LOY-002 could reach the market through the conditional approval pathway before the study concludes. The FDA built this mechanism specifically so that safe, promising drugs don't have to wait a decade to reach patients who need them now.
How much time could it add?
McKenzie was careful here: "Numbers are always tricky, because we tend to fixate on them and think they're more reliable than they are." The STAY study was designed to detect at least a one-year difference between treated and placebo groups. The Purina caloric-restriction precedent suggests two years is possible for some dogs. But the honest answer, until the study concludes, is: meaningfully more time, with better quality.
That framing — better years, not just more years — is actually the more important part. LOY-002 targets the metabolic dysfunction that underlies arthritis, cancer, and cognitive decline simultaneously, rather than treating each condition individually as it appears.
"Arthritis and cancer and cognitive dysfunction are all different things," McKenzie explained, "but really, aging and metabolic health is one aspect that drives all these different things. If we can pick off the underlying driver for all of these things, we can have a much greater impact on health and welfare and wellbeing than just working on each individual disease as it pops up."
The company and the moment
Loyal has raised over $150 million since founding in 2019, including a $100M round that closed earlier this year. CEO Celine Halioua has described this as not just a veterinary story: if a longevity drug can be proven in dogs — a species that shares our environments, our diseases, and our aging patterns — it changes what regulators and scientists believe is possible for human medicine too.
What this means if your dog is getting older
- There is no approved longevity drug for dogs yet — LOY-002 is still in the regulatory process. But the finish line is in sight, and the FDA's formal sign-offs are unprecedented.
- Your vet may already be familiar with Loyal's work given the STAY study's reach across 72 clinics. Worth asking if they're involved.
- Senior dog care today still matters enormously. Weight management, anti-inflammatory nutrition, and regular vet checkups all act on the same metabolic pathways LOY-002 targets — you don't have to wait for a pill to start protecting the years you have.
- Watch this space. The manufacturing acceptance — and with it, conditional FDA approval — could come any time. We'll cover it when it does.
This article is for informational purposes only and is not veterinary advice. Speak with a licensed veterinarian about any health or longevity plan for your dog.